Presentation details are summarized below:
Abstract Title: Comparison of Different Allometric Scaling Approaches to Project Human Pharmacokinetics (PK) of CD388, a Novel Drug-Fc Conjugate, in Development for Influenza Prevention
Presenter: Voon Ong, Ph.D.
Session Title: AAR07 Saturday Antimicrobial Pharmacokinetics and Pharmacodynamics
Presentation Location: Exhibit Hall
Date and Time:
Poster Board Number: AAR-SATURDAY-494
About
Cidara is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak® platform targeting oncologic, viral and autoimmune diseases. Cidara is headquartered in
INVESTOR CONTACT:
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
mfitzhugh@lifescicomms.com
![](https://ml.globenewswire.com/media/MzdiODg4MzktZmNhZC00NzdjLThkYTYtNGE3YjVjNjcxZGEwLTUwMDExMDg1NQ==/tiny/Cidara-Therapeutics-Inc-.png)
2024 GlobeNewswire, Inc., source